glp 1 receptor agonist heart failure The cardiovascular effects of GLP-1 agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action GLP-1 receptor agonists improve cardiovascular

First, we consider findings from post-marketing reports, which represent analyses of data reported to Food and Drug Administration (FDA) by prescribers and/or patients

doi: 10.1016/j.diabres.2016.06.018

BMJ, 335(7631), 1194-1199

In the next section, well explore lifestyle factors that influence GLP-1, followed by guidance on when to work with a clinician, especially for those considering or transitioning off GLP-1 medications

Specific warnings include the risk of aspiration for patients, the need for patients to inform their anaesthetist they are taking these medications, and for anaesthetists to consider the heightened risk of aspiration and to manage such patients accordingly

NCT05520775: Semaglutide for Alcohol Use Disorder Status: Underway This is an early-Phase II human trial using a randomized, placebo-controlled, dose-ranging design to investigate the effects of semaglutide, a GLP-1 receptor agonist, on alcohol-related outcomes in adults with alcohol use disorder